Dr. Liu Hai is a Chief Physician and Associate Professor at Beijing Tiantan Hospital, Capital Medical University. He completed his Ph.D. in 2005 under the supervision of Academician Wang Zhongcheng and has international experience in spinal cord injury research from his time at the University of Rochester and the University of Washington.

Currently, he is a key member of the Office of Scientific and Technological Achievements Transformation at Beijing Tiantan Hospital. Dr. Liu holds several prominent professional affiliations, including committee roles with the Chinese Medical Association, the World Chinese Neurosurgical Society, and the Chinese Rehabilitation Medicine Association, among others.

His research primarily focuses on spinal cord injury, with over 10 SCI-indexed publications. Clinically, he specializes in spinal cord and column tumor treatments, trauma, congenital disorders, and pediatric CNS diseases. Dr. Liu is also leading efforts in translational clinical research and rehabilitation robotics in collaboration with Japanese experts. He has also received numerous competitive research grants and is a reviewer for several international medical journals.

"By welcoming Dr. Liu to our medical advisory board, we gain direct access to the expertise of one of China’s most respected and renowned neurosurgeons. Additionally, his presence strengthens our connections with government officials and the rapidly growing Chinese healthcare market. With Dr. Liu’s support, SensoDetect becomes a strong contender for mental health screening in the largest mental health care initiative in China’s history." – says CEO Per-Anders (PA) Hedin.

For further information, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)73-068 64 20
pa.hedin@sensodetect.com

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of diagnostics, medication, and health. The products are used in both private and public healthcare as a complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

Mer info på https://www.sensodetect.com/